NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida
NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, announced its selection to present at the Wall Street Conference on May 21, 2025 in Palm Beach, Florida. Dr. Jonathan Javitt, Founder, Chairman and CEO of NRx and Co-CEO of HOPE Therapeutics, will provide a company update focusing on progress towards FDA approval of NRX-100 (preservative-free ketamine) and upcoming acquisitions of HOPE clinics specializing in treatment of suicidal depression, PTSD, and related disorders.
The conference, which will host six presenting companies, is expected to attract over 1,000 attendees representing more than $1 trillion in investment capital.
NRx Pharmaceuticals (NASDAQ:NRXP), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione come relatrice alla Wall Street Conference il 21 maggio 2025 a Palm Beach, Florida. Il Dott. Jonathan Javitt, Fondatore, Presidente e CEO di NRx e Co-CEO di HOPE Therapeutics, fornirà un aggiornamento sull'azienda, concentrandosi sui progressi verso l'approvazione FDA di NRX-100 (ketamina senza conservanti) e sulle prossime acquisizioni di cliniche HOPE specializzate nel trattamento della depressione suicidaria, PTSD e disturbi correlati.
La conferenza, che ospiterà sei aziende presentatrici, prevede di attirare oltre 1.000 partecipanti rappresentanti più di 1.000 miliardi di dollari in capitale d'investimento.
NRx Pharmaceuticals (NASDAQ:NRXP), una compañía biofarmacéutica en etapa clínica, anunció su selección para presentar en la Wall Street Conference el 21 de mayo de 2025 en Palm Beach, Florida. El Dr. Jonathan Javitt, fundador, presidente y CEO de NRx y co-CEO de HOPE Therapeutics, ofrecerá una actualización de la compañía enfocándose en los avances hacia la aprobación de la FDA de NRX-100 (ketamina sin conservantes) y las próximas adquisiciones de clínicas HOPE especializadas en el tratamiento de la depresión suicida, PTSD y trastornos relacionados.
La conferencia, que contará con seis empresas presentadoras, se espera que atraiga a más de 1,000 asistentes que representan más de 1 billón de dólares en capital de inversión.
NRx Pharmaceuticals (NASDAQ:NRXP)는 임상 단계의 바이오제약 회사로서, 2025년 5월 21일 플로리다 팜비치에서 열리는 월스트리트 컨퍼런스에서 발표자로 선정되었음을 발표했습니다. NRx의 창립자이자 회장 겸 CEO이며 HOPE Therapeutics의 공동 CEO인 조나단 자빗 박사가 NRX-100(보존제가 없는 케타민)의 FDA 승인 진행 상황과 자살 우울증, PTSD 및 관련 질환 치료에 특화된 HOPE 클리닉의 향후 인수 계획에 대해 회사 업데이트를 제공할 예정입니다.
6개의 발표 기업이 참가하는 이번 컨퍼런스에는 1조 달러 이상의 투자 자본을 대표하는 1,000명 이상의 참석자가 모일 것으로 예상됩니다.
NRx Pharmaceuticals (NASDAQ:NRXP), une société biopharmaceutique en phase clinique, a annoncé sa sélection pour présenter à la Wall Street Conference le 21 mai 2025 à Palm Beach, Floride. Le Dr Jonathan Javitt, fondateur, président et CEO de NRx et co-CEO de HOPE Therapeutics, fournira une mise à jour de l'entreprise en se concentrant sur les progrès vers l'approbation FDA de NRX-100 (kétamine sans conservateurs) et les acquisitions à venir des cliniques HOPE spécialisées dans le traitement de la dépression suicidaire, du PTSD et des troubles associés.
La conférence, qui accueillera six entreprises présentatrices, devrait attirer plus de 1 000 participants représentant plus de 1 000 milliards de dollars en capital d'investissement.
NRx Pharmaceuticals (NASDAQ:NRXP), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, gab bekannt, dass es ausgewählt wurde, auf der Wall Street Conference am 21. Mai 2025 in Palm Beach, Florida, zu präsentieren. Dr. Jonathan Javitt, Gründer, Vorsitzender und CEO von NRx sowie Co-CEO von HOPE Therapeutics, wird ein Unternehmensupdate geben, das sich auf den Fortschritt der FDA-Zulassung von NRX-100 (konservierungsmittelfreies Ketamin) und bevorstehende Übernahmen von HOPE-Kliniken spezialisiert auf die Behandlung von suizidaler Depression, PTSD und verwandten Störungen konzentriert.
Die Konferenz, bei der sechs Unternehmen präsentieren werden, wird voraussichtlich über 1.000 Teilnehmer anziehen, die mehr als 1 Billion US-Dollar an Investitionskapital vertreten.
- None.
- None.
The Wall Street Conference is expected to host over 1,000 attendees who are reported to represent over
NRx will be discussing recent progress towards FDA approval of NRX-100 (preservative-free ketamine) and upcoming acquisitions of HOPE clinics providing state-of-the-art care for suicidal depression, PTSD, and related disorders.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential as well as a treatment for complicated UTI.
NRx has recently initiated a New Drug Application filing for NRX-100 (preservative free IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality and has filed a patent for this novel formulation with the US Patent and Trademark Office.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including, without limitation, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, NRX-100 not being approved by the United States Food and Drug Administration, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy | Brian Korb |
Co-CEO, Hope Therapeutics, Inc. | Managing Partner, ASTR Partners |
Chief Business Officer, NRx Pharmaceuticals, Inc. | (917) 653-5122 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-selected-to-present-at-the-wall-street-conference-on-may-21-2025-in-palm-beach-florida-302461059.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What will NRXP present at the Wall Street Conference 2025?
Who will represent NRXP at the Wall Street Conference 2025?
What is NRX-100 being developed for by NRXP?
How many companies will present at the 2025 Wall Street Conference?
